A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Trial Profile

A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Lixivaptan (Primary)
  • Indications Autosomal dominant polycystic kidney disease; Renal failure
  • Focus Adverse reactions
  • Acronyms ELISA
  • Sponsors Palladio Biosciences
  • Most Recent Events

    • 28 Jun 2018 Planned End Date changed from 1 Mar 2019 to 1 Jun 2019.
    • 28 Jun 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Feb 2019.
    • 28 Jun 2018 Planned initiation date changed from 1 May 2018 to 15 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top